当前位置:药药网 / 数据中心 / 儿科研究特征电子表格
JIVI
通用名称
Antihemophilic Factor (Recombinant), PEGylated-aucl
儿科标签批准日期
2018/8/29 0:00:00
特定指示/秒
Use in previously treated adults and adolescents (12 years of age and older) with hemophilia A (congenital Factor VIII deficiency) for: on demand treatment and control of bleeding episodes; perioperative management of bleeding; and routine prophylaxis to reduce the frequency of bleeding episodes
标签更改摘要
See Package Insert for new information on biologics
治疗类别
Antihemophilic Factor
研究年龄
2 YEARS - 11 YEARS
12 YEARS - 17 YEARS
学习类型
Efficacy,Safety
Efficacy,Safety
研究设计
Multicenter,uncontrolled study,open-label
Multicenter,open-label,uncontrolled study